Contract facts
UnrestrictedNo full NAICS 325412 intel page yet. Browse NAICS intelligence
NUCLEAR MEDICINE IMAGING PRODUCTS FOR MYOCARDIAL INFARCT IMAGING, DIAGNOSTIC IMAGING OF GALL BLADDER DISORDERS, AND BREAST CANCER NODULE IMAGING MEDICINE. is a federal Unrestricted award for Defense Health Agency held by Sun Pharmaceutical Industries, Inc. Estimated value $1M ($967K obligated). Current period of performance ends Mar 10, 2027. Last award drew 3 bidders. Place of performance: BETHESDA MD.
NUCLEAR MEDICINE IMAGING PRODUCTS FOR MYOCARDIAL INFARCT IMAGING, DIAGNOSTIC IMAGING OF GALL BLADDER DISORDERS, AND BREAST CANCER NODULE IMAGING MEDICINE.
Recompete timing
PublicCurrent PoP ends Mar 10, 2027 (164 days remaining). Agencies typically plan 12–18 months ahead — at 5.4 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on HT001422P0039? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordSun Pharmaceutical Industries, Inc — $724K obligated across 7 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT001422P0039?
HT001422P0039 (Nuclear medicine imaging products for myocardial) is a Defense Health Agency award with a potential value of $1M, currently held by Sun Pharmaceutical Industries, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is HT0014-22-P-0039?
HT0014-22-P-0039 is the dashed form of PIID HT001422P0039 (Nuclear medicine imaging products for myocardial), held by Sun Pharmaceutical Industries, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded HT001422P0039?
Defense Health Agency awarded HT001422P0039 to Sun Pharmaceutical Industries, Inc (potential $1M).
Who is the incumbent on HT001422P0039?
Sun Pharmaceutical Industries, Inc is the incumbent with $724K across 7 related awards in SCOUT’s public footprint. The current period of performance ends Mar 10, 2027.
When does Sun Pharmaceutical Industries, Inc’s HT001422P0039 come up for recompete?
SCOUT tracks a period-of-performance end of Mar 10, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on HT001422P0039? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.